Clinical trials: Dementia Severe
Autism Spectrum Disorder, Developmental Disability
Propranolol for Challenging Behaviors in Autism
Severe challenging behaviors such as aggression and self-injury can cause significant morbidity and decrease the quality of life for individuals with Autism Spectrum Disorders (ASD).
- Conditions
- Autism Spectrum Disorder, Developmental Disability, Aggression, Self-Injurious Behavior
- Trial name
- NCT04047355
- Testing
- Propranolol
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Rutgers, The State University of New Jersey
Aggression, Self-Injurious Behavior
Treatment of Severe Destructive Behavior: FCT Versus Wait-List Control
Children with an intellectual disability often display severe destructive behavior (e.g., aggression, self-injury) that pose risks to themselves or others and represent barriers to community integration.
- Trial name
- NCT02483572
- Testing
- Functional Communication Training
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Nebraska
Brain Injuries, Craniocerebral Trauma
DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury
The investigators intend to determine the effect of adrenergic blockade on 1) short-term physiology, behavior, and cognition and 2) long-term neuropsychological outcomes after severe Traumatic Brain Injury (TBI).
- Conditions
- Brain Injuries, Craniocerebral Trauma, Trauma, Nervous System, Traumatic Brain Injury
- Trial name
- NCT01322048
- Testing
- IV Propranolol and Per Tube Clonidine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Vanderbilt University
Alzheimer's Disease
A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.
This was a multicenter, prospective, phase IV study evaluating safety, tolerability and effectiveness of rivastigmine 27 mg -15 cm^2 transdermal patch prescribed in patients with severe dementia of the Alzheimer's type as per…
- Trial name
- NCT02989402
- Testing
- Rivastigmine
- Where
- 9 sites in India
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Problem Behavior, Aggression
Identifying Precursors to Severe Problem Behavior
The primary objective of this research is to evaluate the escalating sequence of behavior that culminates in severe problem behavior (SPB, such as aggression, self-injury, and disruption).
- Trial name
- NCT04097431
- Testing
- Response Blocking
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.